ARK Genomic Revolution ETF (ARKG) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores ARKG 4.0 out of 10 — highest on Growth (8.1), lowest on Quality (0.1). Its ten largest holdings are 59% of the fund.
What stands out in ARKG's data
Genomics and biotech stocks, picked for their growth potential.
Earnings margins trail most peers — the fund's promise rests on future breakthroughs, not current profitability.
EBITDA margin of 4.3% sits behind the category median of 20.5%, and below its own historical median of 5.3%. Top holdings concentration is 58.3%.
A satellite sleeve for portfolios that want direct exposure to biotech innovation.
Why did ARKG move this week? It fell 5.0% in the week to October 9, 2026 — Twist Bioscience and 10X Genomics drove it
ARKG fell 5.0% in the week to October 9, 2026. The holdings that moved it most were Twist Bioscience (−15.3%), 10X Genomics (−13.7%) and Tempus AI (−7.4%); Prime Medicine (+33.9%) pushed the other way.
How is ARKG rated? ETF Copilot scores ARK Genomic Revolution ETF (ARKG) 4.0 out of 10
As of October 9, 2026, ETF Copilot scores ARK Genomic Revolution ETF (ARKG) 4.0 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 4.0 / 10
- Growth: 8.1 / 10
- Risk: 0.2 / 10
- Quality: 0.1 / 10
- Return: 5.2 / 10
What's inside ARKG? 13% AI
What's inside ARKG: Size (Large 13%, Mid 39%, Small 48%); Geography (International 8%, US 92%); AI 13.0%.
What are ARKG's top holdings? The ten largest are 59% of the fund
10X Genomics, Twist Bioscience, Tempus AI, Crispr Therapeutics, Illumina, Natera, Guardant Health, Absci, Caredx and Personalis are ARKG's largest holdings, in that order.
More concentrated than 75% of Health & Biotech ETFs.
Half of ARKG's weight sits in its 8 largest positions, and once those weights are taken into account it behaves like 21 equally weighted holdings.
What is ARKG's expense ratio? 0.75% a year
As of October 9, 2026, ARKG charges 0.75% a year and holds $2.1B in assets across 33 positions.
| Measure | ARKG |
|---|---|
| Expense ratio | 0.75% |
| Assets under management | $2.1B |
| Holdings | 33 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “ARK Genomic Revolution ETF (ARKG) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/arkg
ETF Copilot Pro unlocks ARKG's price and what each holding weighs.
Try Pro free →